Lv11
14 积分 2023-05-19 加入
ICH M12 Drug Interaction Studies: Summary of the Efforts to Achieve Global Convergence
18分钟前
已完结
Transporter-mediated drug-drug interactions: regulatory guidelines, in vitro and in vivo methodologies and translation, special populations, and the blood-brain barrier
4小时前
已完结
Future directions in drug-drug interaction evaluations: Industry perspective on the ICH M12 guidance
7小时前
已完结
Bruton Tyrosine Kinase Degraders Current Concepts
10天前
已完结
PROTAC 2.0: Expanding the frontiers of targeted protein degradation
14天前
已完结
Session 5: Protein Degraders
14天前
已完结
Lessons learned in linking PROTACs from discovery to the clinic
14天前
已完结
Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization towards orally available bifunctional protein degraders
18天前
已完结
Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies
18天前
已完结
Bruton Tyrosine Kinase Degraders Current Concepts
18天前
已完结
皖公网安备34019202002308
